Form 4: Surrozen CEO Acquires Shares and Warrants in Private Placement

Surrozen's CEO, Craig C Parker, acquired common stock and warrants through a private placement, according to a Form 4 filing.

Summary

• Craig C Parker, CEO of Surrozen, Inc., filed a Form 4 disclosing changes in beneficial ownership.
• On April 4, 2024, Parker acquired 1,474 shares of common stock at $16.96 per share through a private placement.
• The acquisition was made pursuant to a Securities Purchase Agreement dated April 1, 2024.
• Parker also acquired warrants to purchase common stock: 1,474 Series A warrants at $16.96, 1,603 Series B warrants at $15.71, 5,712 Series C warrants at $16, and 5,712 Series D warrants at $16.
• The Series B warrants expire five trading days after the Series B Milestone Event or on the fifth anniversary of issuance.
• Series C and D warrants are exercisable for 30 days after the earlier of a Milestone Event or a Fundamental Transaction.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a transaction. The CEO's participation in a private placement could be viewed positively, but it's not definitively bullish.

Positives

• The CEO's participation in the private placement may signal confidence in the company's future prospects.

Risks

• The warrants are subject to milestone events, and failure to achieve these milestones could impact their value.
• The value of the warrants is dependent on the future performance of Surrozen's stock.

Future Outlook

The document does not contain specific forward-looking statements, but the warrant terms are tied to future milestone events.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies and their insiders. This filing indicates the CEO's participation in a private placement, which is a common method for companies to raise capital.

Comparison to Industry Standards

• Private placements are a common fundraising method in the biotechnology industry, especially for companies like Surrozen that are in the development stage.
• The terms of the warrants, such as milestone-based exercisability, are also relatively common in biotech financings, aligning incentives with clinical or regulatory progress.
• Comparing the warrant terms and pricing to similar biotech companies that have recently conducted private placements would provide a more detailed assessment of the deal's favorability.

Stakeholder Impact

• The private placement could dilute existing shareholders.
• The funds raised could be used to advance the company's pipeline, potentially benefiting shareholders in the long term.

Key Dates